Shots:
- The P-III STR1VE-EU study involves assessing Zolgensma (IV) in patients with SMA Type 1 aged <6mos. at the time of gene therapy, with 1 or 2 copies of the SMN2 backup gene and have bi-allelic SMN1 gene deletion or point mutations
- Results: 65.6% achieved motor milestones not observed in the natural history of SMA Type 1, 66.7% were free of feeding support, 93.9% are able to swallow thin liquids, 30.3% required feeding support, 27.3% required ventilatory support; 97% patients in ITT population survived event-free, including 93.8% & 56.3% who could have reached 10.5mos. & 13.6 mos. of age respectively
- New interim P-III STR1VE-EU data presented at WMS support the clinical evidence demonstrating a consistent, transformative benefit across Zolgensma clinical trials for the treatment of patients with SMA
Click here to read full press release/ article | Ref: Novartis | Image: Mint
Related News: Novartis’ Zolgensma (onasemnogene abeparvovec) Receives MHLW’s Approval for Spinal Muscular Atrophy
The post Novartis Reports Results of Zolgensma in P-III STR1VE-EU Study for SMA Type 1 first appeared on PharmaShots.
